Serum levels of TNF-α, sIL-2R, IL-6, and IL-8 are increased and associated with elevated lipid peroxidation in patients with Behcet's disease

被引:198
作者
Evereklioglu, C
Er, H
Türköz, Y
Çekmen, M
机构
[1] Gaziantep Univ, Fac Med, Res Hosp, Dept Ophthalmol, Gaziantep, Turkey
[2] Inonu Univ, Fac Med, Turgut Ozal Med Ctr, Dept Biochem, Malatya, Turkey
关键词
Behcet's disease; chemokine; cytokine; immunoassay; interleukin; lipid peroxidation;
D O I
10.1080/09629350220131935
中图分类号
Q2 [细胞生物学];
学科分类号
071009 [细胞生物学]; 090102 [作物遗传育种];
摘要
AIM Behcet's disease (BD) is a systemic immunoinflammatory disorder and the aetiopathogenesis is to be specified. Cytokines play a role in immune response and in many inflammatory diseases. The aim of this case-control study is to investigate serum pro-inflammatory cytokine tumour necrosis factor (TNF)-alpha, interleukin-1beta (IL-1beta), soluble IL-2 receptor (sIL-2R), IL-6, and chemokine IL-8 levels in patients with BD. We also determined the end product of lipid peroxidation (malondialdehyde (MDA)) in BD patients as an index for oxidative stress. Methods: A total of 37 patients (19 men, 18 women) with BD (active, n = 17; inactive, n = 20) and 20 age-matched and sex-matched healthy control subjects (11 men, nine women) included in this cross-sectional, blinded study. Serum TNF-alpha, IL-1beta, sIL-2R, IL-6 and IL-8 levels were determined by a spectrophotometer technique using the immulite chemiluminescent immunometric assay. Lipid peroxidation was evaluated by Wasowicz et al. The levels of cytokines and lipid peroxidation in the active period were compared with the inactive period of the disease. Results are expressed as mean +/- standard error. Results: IL-1beta levels were below the detection limits of the assay (< 5 pg/ml) in all samples. Mean levels of MDA (8.1 +/- 0.7 μmol/l), sIL-2R (800 +/- 38 U/ml), IL-6 (12.6 +/- 1.1 pg/ml), IL-8 (7.2 +/- 0.4 pg/ml), and TNF-α (7.9 +/- 0.5 pg/ml) in active BD patients were significantly higher than those in inactive patients (4.3 +/- 0.5 μmol/l, p < 0.01; 447 +/- 16 U/ml, p < 0.001; 8.3 +/- 0.6 pg/ml, p = 0.006; 5.3 +/- 0.1 pg/mL p < 0.001; and 5.1 +/- 0.2 pg/ml, p < 0.001; respectively) or control subjects (2.1 +/- 0.2 μmol/l, p < 0.001; 446 +/- 20 U/ml, p < 0.001; 6.4 +/- 0.2 pg/ml, p < 0.001; 5.4 +/- 0.1 pg/ml, p < 0.001; and 4.7 +/- 0.1 pg/ml, p < 0.001, respectively). On the contrary, only the mean IL-6 level was significantly different between inactive BD and control subjects (p = 0.02). All acute phase reactants were significantly higher in active BD than in inactive period (for each,p < 0.01). Conclusions: High levels of sIL-2R, IL-6, IL-8 and TNF-α indicate the activation of immune system in BD. Serum sIL-2R, IL-6, IL-8 and TNF-α seem to be related to disease activity. Increased lipid peroxidation suggests oxidative stress in BD and therefore tissue damage in such patients. Amelioration of clinical manifestations would be envisaged by targeting these cytokines, chemokines and lipid peroxidation with pharmacological agents.
引用
收藏
页码:87 / 93
页数:7
相关论文
共 39 条
[1]
BABSON AL, 1991, J CLIN IMMUNOASSAY, V14, P83
[2]
NEUTROPHIL-ACTIVATING PEPTIDE-1 INTERLEUKIN-8, A NOVEL CYTOKINE THAT ACTIVATES NEUTROPHILS [J].
BAGGIOLINI, M ;
WALZ, A ;
KUNKEL, SL .
JOURNAL OF CLINICAL INVESTIGATION, 1989, 84 (04) :1045-1049
[3]
THE CYTOKINE NETWORK [J].
BALKWILL, FR ;
BURKE, F .
IMMUNOLOGY TODAY, 1989, 10 (09) :299-303
[4]
Immunopharmacology - Immunomodulation and immunotherapy [J].
Ballow, M ;
Nelson, R .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1997, 278 (22) :2008-2017
[5]
Behçet H, 1937, DERMATOL WOCHENSCHR, V105, P1152
[6]
Evaluation of an automated immunoassay method for cytokine measurement using the Immulite® immunoassay system [J].
Berthier, F ;
Lambert, C ;
Genin, C ;
Bienvenu, J .
CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 1999, 37 (05) :593-599
[7]
INTERNATIONAL-UVEITIS-STUDY-GROUP RECOMMENDATIONS FOR THE EVALUATION OF INTRAOCULAR INFLAMMATORY DISEASE [J].
BLOCHMICHEL, E ;
NUSSENBLATT, RB .
AMERICAN JOURNAL OF OPHTHALMOLOGY, 1987, 103 (02) :234-235
[8]
CHRISTEN WB, 1994, AM J MED S, V97, P14
[9]
CHRUMBERS JC, 2001, J AM COLL CARDIOL, V37, P517
[10]
DEVOS AF, 1994, INVEST OPHTH VIS SCI, V35, P3873